Biocon announced that the US FDA conducted a periodic cGMP inspection of the company's Drug Substance manufacturing site at Bangalore Campus from 17-21 September 2018. The weeklong audit concluded without any observations and no Form 483 was issued.

The stock had outperformed the market over the past one month till Sep. 21, 2018, rising 13.05% compared with the Sensex's 3.77% decline. It outperformed the market in past one quarter, gaining 9.87% as against 3.98% rise in the Sensex.

Shares of the company gained Rs 7.05, or 1.04%, to trade at Rs 683.15. The total volume of shares traded was 29,669 at the BSE (9.37 a.m., Monday).